The issuance of new patents is a positive development for ENDRA Life Sciences, as it not only enhances the company's intellectual property portfolio but also potentially opens up new revenue streams through licensing or development of new products. This is likely to be viewed positively by investors, leading to an uptick in the stock price in the short term.